GeneFerm Biotechnology Co Ltd (TWO:1796) — Market Cap & Net Worth
Market Cap & Net Worth: GeneFerm Biotechnology Co Ltd (1796)
GeneFerm Biotechnology Co Ltd (TWO:1796) has a market capitalization of $38.14 Million (NT$1.21 Billion) as of September 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #22994 globally and #1430 in its home market, demonstrating a -3.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GeneFerm Biotechnology Co Ltd's stock price NT$29.20 by its total outstanding shares 41459793 (41.46 Million). Also see GeneFerm Biotechnology Co Ltd balance sheet assets for a full breakdown of the balance sheet.
GeneFerm Biotechnology Co Ltd Market Cap History: 2016 to 2026
GeneFerm Biotechnology Co Ltd's market capitalization history from 2016 to 2026. Data shows change from $97.77 Million to $38.14 Million (-9.62% CAGR). Also see cash efficiency ratio of GeneFerm Biotechnology Co Ltd for how efficiently the company converts equity into cash flow.
GeneFerm Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GeneFerm Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GeneFerm Biotechnology Co Ltd stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.12x
GeneFerm Biotechnology Co Ltd's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $66.29 Million | $349.83 Million | $28.23 Million | 0.19x | 2.35x |
| 2018 | $51.81 Million | $357.45 Million | $10.31 Million | 0.14x | 5.02x |
| 2019 | $38.36 Million | $328.23 Million | -$27.55 Million | 0.12x | N/A |
| 2020 | $36.48 Million | $368.30 Million | $4.53 Million | 0.10x | 8.05x |
| 2021 | $55.73 Million | $522.33 Million | $57.41 Million | 0.11x | 0.97x |
| 2022 | $86.16 Million | $633.96 Million | $93.45 Million | 0.14x | 0.92x |
| 2023 | $97.31 Million | $793.77 Million | $124.62 Million | 0.12x | 0.78x |
| 2024 | $61.39 Million | $521.16 Million | -$22.53 Million | 0.12x | N/A |
Competitor Companies of 1796 by Market Capitalization
Companies near GeneFerm Biotechnology Co Ltd in the global market cap rankings as of September 18, 2026. Review 1796 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GeneFerm Biotechnology Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
GeneFerm Biotechnology Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, GeneFerm Biotechnology Co Ltd's market cap moved from $97.77 Million to $ 38.14 Million, with a yearly change of -9.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$38.14 Million | -39.48% |
| 2025 | NT$63.02 Million | +2.66% |
| 2024 | NT$61.39 Million | -36.91% |
| 2023 | NT$97.31 Million | +12.94% |
| 2022 | NT$86.16 Million | +54.60% |
| 2021 | NT$55.73 Million | +52.78% |
| 2020 | NT$36.48 Million | -4.90% |
| 2019 | NT$38.36 Million | -25.96% |
| 2018 | NT$51.81 Million | -21.84% |
| 2017 | NT$66.29 Million | -32.20% |
| 2016 | NT$97.77 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of GeneFerm Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.14 Million USD |
| MoneyControl | $38.14 Million USD |
| MarketWatch | $38.14 Million USD |
| marketcap.company | $38.14 Million USD |
| Reuters | $38.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company offers microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reis… Read more